论文部分内容阅读
该研究观察了235例同性恋/双性恋男性艾滋病相关综合征(ARC)患者,长期服用叠氮胸苷(AZT),剂量为1200mg/d,服法为200mg每4小时1次,共达5234病人-月(patient-months)后的存活时间,由ARC发展为AIDS的发生率及其时间,以及出现血象、临床副作用等不能耐受用药的因素。同时以12例未经治疗的ARC患者作为对照组。结果发现:用药组发展成AIDS的中位数时间为61周,对照组为22周(P<0.03),前者明显长于后者;用药组发展成AIDS后存活中位数时间为48周,对照组为44周,前者稍长于后者。用药组有68例(29％)
The study looked at 235 patients with homosexual / bisexual men with AIDS-related complex (ARC) who were treated with azithromycin (AZT) at a dose of 1200 mg daily for 200 mg once every 4 hours for a total of 5234 Patient-month survival time, the rate of development of ARC from AIDS to its time, and the factors that can not tolerate medication such as blood clots and clinical side effects. At the same time 12 cases of untreated ARC patients as control group. The results showed that the median time to develop AIDS in the treatment group was 61 weeks and that in the control group was 22 weeks (P <0.03), the former was significantly longer than the latter. The median survival time of the treatment group after AIDS development was 48 weeks, The group was 44 weeks, the former slightly longer than the latter. The medication group had 68 cases (29%)